iCardiac Technologies Launches Global Late Phase Respiratory And Cardiac Safety Study Spanning 28 Countries
The Phase III trial, the largest in the company’s history, will assess 14,000 subjects across 750 sites
February 24, 2016, Rochester, NY - iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today announced it was awarded and is now enrolling patients in the largest late phase respiratory and cardiac safety study in the company’s history.
The three-year clinical trial will be conducted at sites across 28 countries and will include approximately 340,000 pulmonary function tests and 90,000 ECG reviews. iCardiac acquired the clinical trials division of nSpire Health in July 2015 and now offers both respiratory and cardiac safety assessment services to drug developers.
“iCardiac has the capacity and the expertise to support sponsors whether they are doing a small Phase II study with 10 sites or a large study with 750 sites,” said Brian Smith, Vice President of Project Operations, at iCardiac. “And whether a study is large or small, iCardiac continues to set itself apart based on our dedication to flexibility and study support, as well as the innovation embedded in our technology.”
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for cardiac safety and respiratory services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.
February 24, 2016, Rochester, NY - iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today announced it was awarded and is now enrolling patients in the largest late phase respiratory and cardiac safety study in the company’s history.
The three-year clinical trial will be conducted at sites across 28 countries and will include approximately 340,000 pulmonary function tests and 90,000 ECG reviews. iCardiac acquired the clinical trials division of nSpire Health in July 2015 and now offers both respiratory and cardiac safety assessment services to drug developers.
“iCardiac has the capacity and the expertise to support sponsors whether they are doing a small Phase II study with 10 sites or a large study with 750 sites,” said Brian Smith, Vice President of Project Operations, at iCardiac. “And whether a study is large or small, iCardiac continues to set itself apart based on our dedication to flexibility and study support, as well as the innovation embedded in our technology.”
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for cardiac safety and respiratory services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.